Actinomycin-D clinical trials
Actinomycin-D is named as an intervention in 3 current clinical trials in our China, Ireland, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Australia and Israel registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Peking Union Medical College Hospital (2). The most-studied condition is Gestational Trophoblastic Neoplasia.
Patient leaflets for Actinomycin-D
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Actinomycin-D
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7
NCT06020755 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia
|
Phase 2 | Recruiting | Peking Union Medical College Hospital | China |
|
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907 · Rhabdomyosarcoma
|
Phase 1/2 | Recruiting | University of Birmingham | Ireland, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Australia, Israel |
|
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
NCT06028672 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia
|
Not applicable | Recruiting | Peking Union Medical College Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Actinomycin-D
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College Hospital | 2 |
| University of Birmingham | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Actinomycin-D trials
How many clinical trials are testing Actinomycin-D?
3 current trials in our China, Ireland, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Australia and Israel registers name Actinomycin-D as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Actinomycin-D trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 2 with sites in China, 1 with sites in Ireland, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Norway, 1 with sites in Portugal, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Actinomycin-D clinical trials?
Peking Union Medical College Hospital (2) and University of Birmingham (1). The number in brackets is how many trials each organisation leads.
Are there Actinomycin-D clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Actinomycin-D works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Actinomycin-D works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Actinomycin-D (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.